Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
News
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/ee/36/b7/ee36b702-2a97-c047-0f32-c339c6acc027/mza_11381342764586184688.jpg/600x600bb.jpg
Perspectives by the Leerink Center for Pharmacoeconomics
The Leerink Center for Pharmacoeconomics
13 episodes
3 days ago
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a pa...
Show more...
Investing
Business
RSS
All content for Perspectives by the Leerink Center for Pharmacoeconomics is the property of The Leerink Center for Pharmacoeconomics and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a pa...
Show more...
Investing
Business
Episodes (13/13)
Perspectives by the Leerink Center for Pharmacoeconomics
David Hong, MD, Steve Potts, PhD, MBA, and Vivek Subbiah, MD talk Pan-Tumor Approvals in a Post-IRA World
1 month ago
42 minutes

Perspectives by the Leerink Center for Pharmacoeconomics
Head of the Leerink Center for Pharmacoeconomics, Melanie Whittington, PhD
2 months ago

Perspectives by the Leerink Center for Pharmacoeconomics
Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech
3 months ago

Perspectives by the Leerink Center for Pharmacoeconomics
The IP Policy Institute’s Joshua Kresh and Emily Michiko Morris
4 months ago

Perspectives by the Leerink Center for Pharmacoeconomics
Director of Access and Policy Research at Johnson & Johnson, Ulrich Neumann, MBA, MSc, MA
4 months ago

Perspectives by the Leerink Center for Pharmacoeconomics
Head of Patient Engagement and Patient-Centered Innovation, Raven, RA Capital's healthcare incubator, Gunnar Esiason, MBA, MPH
5 months ago

Perspectives by the Leerink Center for Pharmacoeconomics
Vice Chair of Research and Associate Professor, University of Utah, Joey Mattingly, PharmD, MBA, PhD
6 months ago

Perspectives by the Leerink Center for Pharmacoeconomics
Chief Science Officer, National Pharmaceutical Council, Jon Campbell, PhD
7 months ago
33 minutes

Perspectives by the Leerink Center for Pharmacoeconomics
Head of U.S. Public Affairs and Patient Advocacy, Oncology with Sanofi, Elizabeth Franklin, PhD, MSW
8 months ago
34 minutes

Perspectives by the Leerink Center for Pharmacoeconomics
Senior Policy Advisor at DLA Piper & Non-Resident Fellow at the American Enterprise Institute, Kirsten Axelsen
9 months ago
25 minutes

Perspectives by the Leerink Center for Pharmacoeconomics
Managing Director of Pharmagellan and Professor of the Practice at Tufts University, Frank S. David, MD, PhD
10 months ago
38 minutes

Perspectives by the Leerink Center for Pharmacoeconomics
Author of the Cost Curve & the Principal and Founder of Reid Strategic, Brian Reid
11 months ago
32 minutes

Perspectives by the Leerink Center for Pharmacoeconomics
Welcome to Perspectives by the Leerink Center for Pharmacoeconomics
1 year ago

Perspectives by the Leerink Center for Pharmacoeconomics
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a pa...